Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irosustat

Next Previous
X
Search
Drug Profile

Irosustat

Alternative Names: 6,6,7-COUMATE; BN 83495; Irostustat; oristusane; STX 64PC; STX-64

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipsen
  • Developer Ipsen; Peter MacCallum Cancer Centre
  • Class Antineoplastics; Sulfonic acids
  • Mechanism of Action Steryl sulfatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 11 Mar 2016 Discontinued - Phase-II for Breast cancer (Neoadjuvant therapy) in United Kingdom (PO)
  • 11 Mar 2016 Ipsen terminates phase II trial in Breast cancer (Neoadjuvant therapy) in United Kingdom (NCT01662726)
  • 13 Aug 2015 No recent reports on development identified - Phase-II for Breast cancer (Neoadjuvant therapy) in United Kingdom (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top